Lavipharm

Lavipharm ROIC

The Return on Invested Capital (ROIC) of Lavipharm (LAVI.AT) as of Nov 2, 2026 is 7.06 %. In the previous year, Return on Invested Capital (ROIC) was 10.35 % — a change of -31.73% (lower).

ROIC

7.06 %

YoY

-31.73%

Last updated:

Return on Invested Capital (ROIC) of Lavipharm is 2025 7.06 % . Return on Invested Capital (ROIC) of Lavipharm was 2024 10.35 % . It decreases by -31.73% lower compared to the previous year.

The Lavipharm ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
5.94 EUR
Jan 1, 2019
20.25 EUR
Jan 1, 2020
8.74 EUR
Jan 1, 2021
6.30 EUR
Jan 1, 2022
1.08 EUR
Jan 1, 2023
2.49 EUR
Jan 1, 2024
10.35 EUR
Jan 1, 2025
7.06 EUR
The Lavipharm ROIC history
YEARROICYoY
7.06 %-31.73%
10.35 %+315.45%
2.49 %+131.02%
1.08 %-82.88%
6.30 %-27.93%
8.74 %-56.83%
20.25 %+240.67%
5.94 %-90.08%
59.94 %+673.66%
7.75 %-150.39%
-15.38 %-74.39%
-60.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

Return on Invested Capital (ROIC) of Lavipharm is 7.06 % in 2025.

Return on Invested Capital (ROIC) of Lavipharm changed from 10.35 % to 7.06 %, representing a -31.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Lavipharm since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Lavipharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Lavipharm

All Key Metrics — Lavipharm